Søgning
Søgning på udtrykket 'rsv' giver 42 resultater
Nyt fra tidsskrifterne [+20] Aktuelle smitsomme sygdomme [+20]
…er som følger: 1) Det vises for første gang, at et medikament kan reaktivere latent HIV-virus under samtidig HAART-behandling i en grad, så virus kan påvises i perifert blod. 2) Der er (omend videnskaligt svage) indicier på, at HIV-reservoir kan reduceres hos nogle patienter, og at effekten af det innate immunforsvar er af betydning herfor. 3) Det er den første originalartikel trykt i den allerførste udgave af et helt nyt HIV-tidsskrift (som formentlig vil blive et betydende tidsskrift på området).
…n (per oralt) blev undersøgt på ca. 700 Vietnamesiske patienter. Men der kunne desværre ikke erkendes nogen forskel i de to grupper. I en leder i samme nummer af NEJM henleder Peter Donald opmærksomheden på de gode behandlingsresultater man har i Cape Town med et kun 6 måneders regime som inkluderer Ethionamid (Trecator), Isoniazid, Rifamipcin og Pyrazinamid. Hvem har herefter opskriften på et nyt, etisk forsvarligt, klinisk studie til behandling af en af de mest alvorlige neuroinfektioner vi kender?
Nyt fra tidsskrifterne [+20]
Der er mere end 20 resultater, måske du vil se flere resultater her?
Journal of Medical Virology
14.06.2025
Journal of Medical Virology, Volume 97, Issue 6, June 2025.
Clinical Infectious Diseases
13.06.2025
Abstract . Background . Cardiovascular complications contribute to adverse outcomes in patients with influenza and SARS-CoV-2 infections. While the association of RSV infection with cardiovascular events (CVE) has been described, data are limited.Methods . We performed a retrospective study of hospitalized patients with RSV in Rochester, NY, during the 2017-2020 winter seasons…
JAMA Network Open New Online
12.06.2025
This decision analytical model study estimates the number of respiratory syncytial virus (RSV) hospitalizations averted due to new RSV immunization strategies in King County, Washington, and provides scenario projections for future seasons.
Lancet Infectious Diseases
11.06.2025
Chile's nirsevimab immunisation strategy significantly reduced RSV-related LRTI hospitalisations and more severe cases requiring intensive care. Our findings indicate a broader public health impact, with reductions also observed in all-cause LRTI hospitalisations. These results might encourage other countries to advance RSV prevention efforts.
Clinical Infectious Diseases
4.06.2025
Abstract . Background . Respiratory syncytial virus (RSV) is a significant health risk for adults aged 18-59 years with chronic medical conditions.Methods . This ongoing, randomized, double-blind Phase 3 trial evaluates safety and immunogenicity of the RSV vaccine, mRNA-1345, in adults aged 18-59 years at increased risk for RSV-associated lower respiratory tract disease (LRTD). Participants received a single 50-µg (licensed dose) or 30-µg dose…
Lancet Respiratory Medicine
28.05.2025
A single RSVPreF3 OA dose was efficacious against RSV-LRTD over three RSV seasons in people aged 60 years or older, despite a decrease in efficacy over time. Further research is needed to establish the optimal revaccination strategy. These results support the favourable benefit–risk profile of RSVPreF3 OA to help protect against RSV-LRTD for at least three RSV seasons.
JAMA Network Open New Online
23.05.2025
This cross-sectional study assesses the risk of cardiovascular complications in a nationwide cohort of Singaporean adults hospitalized for respiratory syncytial virus, influenza, or COVID-19 during community transmission of Omicron XBB/JN.1 subvariants.
Journal of the American Medical Association
7.05.2025
This study examines respiratory syncytial virus (RSV) genomic surveillance results from 2 large US networks after the introduction of RSV vaccines.
BMC Infectious Diseases
7.05.2025
. Background. Lower respiratory infections are the leading cause of illness and death in children under 5, primarily due to respiratory syncytial virus(RSV). Climate and pollution influence disease and pathogen prevalence. This study investigates the correlation between meteorological factors, atmospheric pollutants, and RSV infections in children, aiming to implement effective clinical measures and reduce RSV risk in children by enhancing the environment. …
Lancet Infectious Diseases
6.05.2025
These real-world estimates for the 2024 RSV season in Argentina show high RSVpreF effectiveness against RSV-associated LRTD and severe LRTD leading to hospitalisation from birth to age 3 months and sustained to age 6 months.
Journal of Infectious Diseases
6.05.2025
Abstract . Respiratory syncytial virus (RSV) infections are a significant public health concern for pediatric populations and older adults, with seasonal winter outbreaks in the United States (US). Little is known about the timing of RSV epidemics across age groups and the relative contribution of within-group and between-group transmission of RSV in each age group. In this study, we analyzed RSV timing and transmission across age groups in 12 states from 2018 to 2024…
Journal of Medical Virology
1.05.2025
Journal of Medical Virology, Volume 97, Issue 5, May 2025.
Journal of Infectious Diseases
19.04.2025
Abstract . Background . Most epidemiologic studies and clinical testing use a single nasal/nasopharyngeal swab for RSV detection. Previous studies have documented that RSV detection improves if a single additional specimen is added to nasal/nasopharyngeal swab, but the impact of using multiple specimen types has not been assessed. We quantified RSV the increase in RSV detection using multiple specimen testing compared to nasopharyngeal swab (NPS) alone.Methods …
Journal of Medical Virology
12.04.2025
Journal of Medical Virology, Volume 97, Issue 4, April 2025.
JAMA Network Open New Online
11.04.2025
This cohort study assesses risk factors associated with severe clinical outcomes among children hospitalized with respiratory syncytial virus–associated acute respiratory tract infections in 2022 and 2023.
BMJ Open
6.04.2025
. Objectives. To describe the post-marketing safety profile of respiratory syncytial virus prefusion F (RSVpreF) vaccine among pregnant individuals. . Design. This study analysed adverse event (AE) reports submitted to the U.S. Food and Drug Administration’s Vaccine Adverse Event Reporting System (VAERS) database following RSVpreF immunisation from 1 September 2023 to 23 February 2024. . Setting…
Journal of Infectious Diseases
5.04.2025
Abstract . Background . Little is known about the strength and durability of protection (CoP) provided by pre-F IgG after RSV infection/exposure.Methods . We analyzed 1,019 sera from 422 individuals in 173 households, collected 365 days before and after RSV infection or exposure (2014-2022), from a longitudinal cohort with active respiratory infection surveillance. IgG against RSV pre-F was measured by electrochemiluminescence assay…
Journal of Infectious Diseases
5.04.2025
Abstract . Background . We estimated RSV and hMPV illness incidences among pregnant women and examined the association between antenatal RSV illness and preterm birth and small for gestational age (SGA).Methods . Pregnant women aged ≥18 years were followed twice weekly until the end of pregnancy to identify illness episodes with >1 of myalgia, cough, runny nose/nasal congestion, sore throat, or difficulty breathing…
Journal of the American Medical Association
26.03.2025
The respiratory syncytial virus (RSV) vaccines marketed as Abrysvo by Pfizer and Arexvy by GSK will now require a warning about the risk of Guillain-Barré syndrome (GBS), the US Food and Drug Administration (FDA) announced recently.
Journal of Infectious Diseases
25.03.2025
Abstract . Background . Immunity to RSV is short-lived following infection. We determined if recently licensed RSV preF vaccines induce better immune responses than infection.Methods . Serum preF binding and neutralizing antibody to RSV A and B was measured in older adults at baseline and 30 days after RSV infection or vaccination with two licensed RSV preF protein vaccines.Results . Vaccination induced higher serum preF binding antibody and neutralizing responses than RSV infection (A2 RSV: 3306 vs 1254, p
Aktuelle smitsomme sygdomme [+20]
Der er mere end 20 resultater, måske du vil se flere resultater her?
Medscape Infectious Diseases
17.06.2025
A U.S. government scientist who oversees the team responsible for collecting data on COVID-19 and RSV hospitalizations used to shape national vaccine policy has resigned,. . Reuters Health Information
Medscape Infectious Diseases
13.06.2025
GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults below the age of 50 who are at risk of the disease,. . Reuters Health Information
Medscape Infectious Diseases
13.06.2025
The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a lower group of adults aged 18 to 59 years at. . Reuters Health Information
Medscape Infectious Diseases
11.06.2025
The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during. . Reuters Health Information
Medscape Infectious Diseases
27.05.2025
Universal immunisation with nirsevimab significantly reduces hospitalizations and paediatric intensive care admissions for respiratory syncytial virus–associated infections in young infants. . Medscape News UK
Eurosurveillance latest updates
24.05.2025
. Background. Data on economic costs of respiratory syncytial virus (RSV) infections among children in primary care are scarce, although most RSV-infections are managed in this setting. . . Aim. To estimate outpatient costs for RSV-positive children aged
Medscape Infectious Diseases
13.05.2025
Interim surveillance network data showed lower hospitalization rates following the availability of prevention products. . Medscape Medical News
Medscape Infectious Diseases
8.05.2025
Most infants hospitalised for RSV-related infections need oxygen support and critical care despite nirsevimab use, with similar severity across cases, a Spanish study shows. . Medscape News UK
Medscape Infectious Diseases
8.05.2025
The overall uptake of RSV vaccine is low during its first season in those aged 60 years or older in the United States. The knowledge of the vaccine and its eligibility is limited. . Medscape Medical News
Medscape Infectious Diseases
18.04.2025
The panel was due to vote on influenza vaccine recommendations but delayed that to its June meeting. . Medscape Medical News
Medscape Infectious Diseases
17.04.2025
The U.S. Centers for Disease Control and Prevention's panel of outside experts on Wednesday recommended the use of respiratory syncytial virus vaccines in younger adults who. . Reuters Health Information
Medscape Infectious Diseases
11.04.2025
Australians are preparing for significant numbers of respiratory infections this winter, as cases of influenza, RSV, and pertussis surge earlier than expected. . Medscape Medical News
Medscape Infectious Diseases
2.04.2025
Genomic sequencing shows most household spread of RSV is by children aged 6 months to 12 years. . Medscape Medical News
Medscape Infectious Diseases
24.03.2025
The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated lower respiratory tract illness in people aged ≥ 60 years. . Medscape Medical News
Medscape Infectious Diseases
19.03.2025
After COVID-19, RSV cases appear earlier and result in more severe illness in infants, with increased oxygen and ventilation needs, a new study reports. . Medscape News UK
Medscape Infectious Diseases
18.03.2025
A single dose of respiratory syncytial virus vaccine was effective against infections and associated hospitalizations in veterans aged at least 60 years during the 2023-24 season. . Medscape Medical News
Medscape Infectious Diseases
1.03.2025
Britain's health regulator said on Friday it has approved Moderna's vaccine for respiratory syncytial virus in adults 60 years and older. . Reuters Health Information
Medscape Infectious Diseases
25.02.2025
A young woman’s repeated loss of consciousness is traced to severe anaemia caused by warm autoimmune haemolytic anaemia, a rare complication of respiratory syncytial virus. . Medscape News UK
Medscape Infectious Diseases
25.02.2025
A cohort study found that nearly three fourths of infants received respiratory syncytial virus protection with either nirsevimab or through exposure to maternal RSVpreF in the 2023-2024 season. . Medscape Medical News
Infants needed to immunise with nirsevimab to prevent one RSV hospitalisation, Spain, 2023/24 season
Eurosurveillance latest updates
14.02.2025
Using real-life data from Spain between October 2023 and March 2024, the number needed to immunise (NNI) with nirsevimab and the cost to prevent one RSV hospitalisation were estimated at 90 infants (95% CI: 77–108) and 19,700 EUR for catch-up immunisation, and 41 infants (95% CI: 35–50) and 9,000 EUR for at-birth immunisation. By month of birth, NNI and cost were lowest in infants born shortly before the RSV epidemic peak, with impact decreasing gradually for earlier or later births. .